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Abstract
Background: HuR, an RNA binding protein involved in the post-transcriptional regulation of a wide spectrum of
mRNAs, has been demonstrated to be a determinant of carcinogenesis and tumor aggressiveness in several cancer
types. In this study, we investigated the role of HuR in the apoptosis and in the chemoresistance induced by the
widely used anticancer drug doxorubicin in human breast cancer cells (MCF-7).
Results: We showed that HuR acts in the early phase of cell response to doxorubicin, being induced to translocate
into the cytoplasm upon phosphorylation. Reducing HuR levels diminished the apoptotic response to doxorubicin.
Doxorubicin-induced apoptosis was also correlated with the presence of HuR in the cytoplasm. Rottlerin, which
was able to block HuR nuclear export, had correspondingly antagonistic effects with doxorubicin on cell toxicity.
The proapoptotic activity of HuR was not due to cleavage to an active form, as was previously reported. In in vitro
selected doxorubicin resistant MCF-7 cells (MCF-7/doxoR) overexpressing the multidrug resistance (MDR) related
ABCG2 transporter, we observed a significant HuR downregulation that was paralleled by a corresponding
downregulation of HuR targets and by loss of rottlerin toxicity. Restoration of HuR expression in these cells
resensitized MCF-7/doxoR cells to doxorubicin, reactivating the apoptotic response.
Conclusions: The present study shows that HuR is necessary to elicit the apoptotic cell response to doxorubicin
and that restoration of HuR expression in resistant cells resensitizes them to the action of this drug, thereby
identifying HuR as a key protein in doxorubicin pharmacology.
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Background
Insurgence of drug resistance during chemotherapy is a
major cause of cancer relapse and consequent failure of
therapy for cancer patients. Genetic and epigenetic
changes, resulting in gene expression reprogramming,
play a major role in allowing adaptation to the presence
of anticancer drugs [1]. One of the most important
aspects of this phenomenon is the development of resis-
tance and cross resistance to drugs having a mechanism
of action unrelated to the single chemotherapeutic agent
originally causing resistance, i.e. the MultiDrug Resis-
tance phenotype (MDR) [2]. Resistance mechanisms are
extremely complex, changing according to the type of
drug that was used in therapy and spanning from the
overexpression of drug extrusion pumps, as in the case of
several cytotoxic compounds [3], to mutations or overex-
pression of the pharmacological target, as in the case of
receptor tyrosine kinase inhibitors [4]. In the case of dox-
orubicin (doxo), a widely used chemotherapeutic agent,
different mechanisms responsible for the onset of a drug
resistant phenotype in cancer cell models have been
recognized. The most common is characterized by
enhanced expression of the P-glycoprotein, ABCB1 [5], a
transmembrane pump responsible for drug efflux from
cells. P-glycoprotein belongs to the family of ATP bind-
ing-cassette (ABC) transporters. Another member of this
family, ABCG2, was more recently identified as involved
in drug resistance to doxo as well [6]. The expression
level of topoisomerase II [7,8], the molecular target of
doxo, is another major factor implicated in doxo
* Correspondence: provenzani@science.unitn.it
1Laboratory of Genomic Screening, Centre for Integrative Biology, CIBIO,
University of Trento, Trento, Italy
Full list of author information is available at the end of the article
Latorre et al. Molecular Cancer 2012, 11:13
http://www.molecular-cancer.com/content/11/1/13
© 2012 Latorre et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
pharmacoresistance. Since doxo stimulates cell apoptosis
through inhibition of topoisomerase II and consequent
DNA damage, cells develop resistance by downregulating
this enzyme [9].
Translational control is recognized as an increasingly
important level of regulation of gene expression [10], but
its impact in drug resistance has not yet been addressed
fully. Among the major agents involved in translational
control, the RNA binding protein (RBP) HuR is a pleiotro-
pic protein [11] regulating many physiological processes.
HuR acts as a mRNA stabilizer and/or a translational
enhancer that binds to a large number of AU-rich element
(ARE) containing mRNAs [12,13]. Many of the genes con-
trolled by HuR are implicated in important physiological
functions, such as embryonic development [14,15] and cell
differentiation [16]. HuR overexpression or preferential
cytoplasmic localization has been correlated with carcino-
genesis in tissue biopsies and in cell models [17-19] and
patient negative prognosis [20]. A caspase-truncated form
of HuR has also been identified as a promoter of cell death
[21,22].
In this work we explored the possibility that the involve-
ment of HuR in the apoptotic response could contribute
to the development of the resistance phenotype. First we
show that HuR undergoes cytoplasmic translocation in
MCF-7 cells exposed to doxo, and that this translocation
is necessary to the doxo-induced triggering of apoptosis.
We finally show that restoration of HuR expression in
doxo-resistant, HuR-downregulating MDR cells is suffi-
cient to reacquire sensitivity to this anticancer drug.
Results
Doxorubicin induces HuR phosphorylation and
nucleocytoplasmic shuttling
Since HuR is induced to relocate from the nucleus to the
cytoplasm following DNA damaging stimuli such as UVR
[23], we reasoned that an anticancer agent known to
induce DNA damage as doxorubicin (doxo) could pro-
duce a similar effect. We starved MCF-7 cells for 24 h in
order to induce nuclear localization of HuR (Figure 1A,
B) [24]. Indeed, after 4 h of doxo addition, HuR translo-
cated into the cytoplasm. The translocation effect was
proportional to the applied dose, as quantified by calcu-
lating the ratio of the signal intensity of the protein in
the nucleus versus the cytoplasm (Figure 1A). The total
amount of HuR inside the cells did not change after doxo
administration, as measured by densitometric analysis of
three independent western blots (Figure 1B). As can be
seen in Figure 1C and 1D, HuR began to accumulate in
the cytoplasm after 1 h of 10 μM doxo addition. After 4
h, a two fold enrichment of the proteins was observed in
the cytoplasm over the control condition (Figure 1D).
Moreover, within the time frame of the experiment and
notwithstanding the known cell damage induced by doxo
that can result in the potential loss of nucleocytoplasmic
compartmentalization, the nuclear membrane was still
intact since nuclear and cytoplasmic markers (H3 and
LDH, respectively) were clearly confined in their com-
partments while HuR accumulated in the cytoplasm.
Since HuR shuttling is the consequence of post-transla-
tional modifications, including phosphorylation [25,26]
we evaluated if doxo induced HuR phosphorylation.
Lysates of cells treated with doxo resulted in the migra-
tion of HuR in a 2D Western blot stained with anti-HuR
antibody at pH values lower than the pI of the native pro-
tein, which suggested that a series of phosphorylation
events may have occurred after treatment with the drug.
The bands were no longer visible after treatment of the
lysates with alkaline phosphatases, consistent with the
presence of phosphoryl groups (Figure 1E). This result
was confirmed by immunoprecipitating HuR under the
same experimental conditions and blotting with anti pan
Ser/Thr antibody. A phosphorylation band was observed
in the control reaction, i.e. in the presence of the serum,
was absent during starvation, and reappeared after doxo
administration. These findings suggest that doxo induces
phosphorylation of HuR and accumulation of HuR in the
cytoplasm, as is often observed with other DNA dama-
ging treatment such as cisplatin [27].
Apoptosis by doxorubicin is dependent on HuR
phospohorylation and cytoplasmic translocation
We investigated if HuR translocation was involved in
doxo-induced cell death. Initially we evaluated the apopto-
tic response following doxo treatment in the presence and
absence of HuR expression in a dose and time dependent
manner. The apoptotic response to doxo was measured by
the activation of caspase 3 and caspase 7 and by the expo-
sure of phosphatidylserine on the outer leaflet of the
plasma membrane (Additional file 1: Figure S1). We tran-
siently transfected MCF-7 cells with a siRNA against HuR
(Figure 2B) and found, as shown in Figure 2A, that caspase
activation was lower in HuR silenced cells compared to
control cells. The decrease of caspase activation was signif-
icant after 4 h at 10 nM, 100 nM and 1 μM doxo. We then
tested if this effect could be obtained also by blocking
doxo-induced HuR phosphorylation by exploiting the
known HuR phosphorylation inhibitor rottlerin [28]. Rot-
tlerin administration to starved MCF-7 cells did not influ-
ence HuR phosphorylation and slightly influenced the
outflow of the protein from the nucleus (Figure 2C, D).
However, rottlerin had a strong inhibitory impact on the
activation of its first recognized pharmacological target
PKCδ (Figure 2F), showing the effectiveness of this drug in
this cell line. We measured the apoptotic effect of rottlerin
and found that it did not induce an apoptotic response
even with a 10 mM dose after a 4 h exposure. Synchro-
nous coadministration of doxo and rottlerin did not
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Figure 1 A: HuR translocates from the nucleus to the cytosol after doxorubicin treatment. Immunofluorescence (HuR in green,
counterstaining DAPI in blue) on MCF-7 cells starved for 24 h and treated at increasing doxo concentration (from 1 to 50 μM) for 4 h.
Quantification of HuR cytoplasmic translocation measured on immunofluorescence images by calculating the ratio of intensity signal in the
nucleus and in the cytoplasm. An average of 300 cells for each experimental conditions were used. Z-score below zero indicates nuclear
localization, above zero cytoplasmic localization. B: Subcellular fractionation on increasing doses of doxorubicin and quantification of HuR
expression level. Western blotting on MCF-7 cells starved for 24 h and treated at increasing doxorubicin concentration (from 1 to 50 μM). The
filter was probed with anti-H3 as nuclear fraction marker and anti-LDH as a cytosolic fraction marker. Quantification of total HuR protein
measured by densitometric analyses on three independent western blots. C: HuR translocates from the nucleus to the cytosol after 1 and 4
h doxorubicin treatment. Immunofluorescence (HuR in green, counterstaining DAPI in blue) on MCF-7 cells starved or not (FCS) for 24 h and
treated with doxorubicin 10 μM for 1 and 4 h. D: Subcellular fractionation after 1 and 4 h doxorubicin treatment. Western blotting on MCF-
7 cells starved or not (FCS) for 24 h and with doxorubicin 10 μM for 1 and 4 h. The filter was probed with anti-H3 as nuclear fraction marker
and anti-LDH as a cytosolic fraction marker. Quantification of HuR protein translocation after 10 μM doxo for 4 h measured by densitometric
analyses on three independent western blots. * p-value < 0.01 with respect to starved conditions. E: Doxorubicin induces modification in HuR
phosphorylation. 2D western blotting on whole cell lysates. MCF-7 cells were grown in standard condition (FCS), starved or in the presence of
doxorubicin 10 μM for 4 h (doxo). As negative control for phosphorylation the doxorubicin sample was treated with calf intestinal alkaline
phosphatase (CIAP). HuR immunoprecipitation blotted with anti HuR and pan anti-phospo antibody. As negative control IgG
immunoprecipitation was blotted with anti HuR and pan anti-phospo antibodies. In: Input material, IgG: IgG immunoprecipitated material, HuR:
anti-HuR immunoprecipitated material.
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Figure 2 A: HuR is necessary for caspase 3/7 activation doxorubicin induced. Histogram shows the caspase 3/7 activation (as luciferase
intensity) in MCF-7 cells in the presence of increasing doxorubicin concentration with (light grey bar) or without (dark gray bar) HuR silencing.
Graph of a representative experiment out of three experiments. Experiments were run in quadruplicate. * p-value < 0.01 with respect to HuR
silenced cells. B: HuR silencing. Immunofluorescence on MCF-7 cells at 24 h after the siRNA HuR transfection. HuR is represented in green,
counterstaining DAPI is blue. C: Doxorubicin induced HuR phosphorylation is blocked by rottlerin. 2D gel western blots on whole MCF-7
cell lysates cells treated with Rottlerin 10 mM for four hours and in co-administration with doxo. HuR immunoprecipitation blotted with anti HuR
and pan anti-phospo antibodies. As negative control IgG immunoprecipitation was blotted with anti HuR and pan anti-phospo antibodies. In:
Input material, IgG: IgG immunoprecipitated material, HuR: anti-HuR immunoprecipitated material. The drug was tested for its capacity to modify
HuR phosphorylation status alone or together with doxorubicin (doxo). Control for doxo alone is shown in Figure 1E D: HuR localization.
representative immunofluorescence images of HuR localization (green) in control conditions (FCS, starvation, doxo) and in the presence of
Rottlerin and with pre-treatment with one hour Rottlerin and four hours doxo. Images indicate that Rottlerin blocks doxo induced HuR
translocation. E. Apoptotic response activation of MCF-7. Histogram shows the caspase 3/7 activation (as luminescent intensity) of MCF-7 cells
in the presence of rottlerin (light grey) or rottlerin with doxorubicin (dark gray). Graph of a representative experiment out of three experiments.
Experiments were run in quadruplicate. NS, Not Significant with respect to control (CTRL), * p-value < 0.01 with respect to doxorubicin
treatment. F. Rottlerin blocks PMA induced PKCδ activation. representative confocal immunofluorescence images of PKCδ localization (green)
in control conditions (FCS, rottlerin, PMA) and in the presence of coadministration of Rottlerin and PMA. Images indicate that Rottlerin blocks
PMA induced PKCδ membrane translocation, known mechanism of PKCδ activation.
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increase the apoptotic response with respect to doxo single
treatment (Figure 2E). We then preincubated starved cells
for 1 h with rottlerin and then added doxo for 4 h. In this
condition rottlerin hampered doxo-induced phosphoryla-
tion of HuR (Figure 2C) and prevented its cytoplasmic dif-
fusion (Figure 2D). A functional interaction of rottlerin
and doxo could be also detected by measuring cell viabi-
lity, which was determined by an ATP dependent lumines-
cence-based method. Doses of rottlerin and doxo, both
separately and in association, ranged from 0.1 nM to 10
μM for a 24 h exposure. The IC50 values in Table 1 show
the effect of the administration of the compounds on the
proliferation of the MCF-7 cells. Rottlerin exerted an
activity in the low nanomolar range, while doxo IC50 was
40 nM, less potent than rottlerin. The combination effect
was calculated by the Loewe index, maintaining a fixed
concentration ratio of 10:1 between rottlerin and doxo. As
shown in Figure 3B, the combination index was signifi-
cantly above one for the entire fraction of cells affected by
the drugs, indicating that the coadministration induced an
effect which was less severe than would be expected from
the sum of the effects that each drug would produce on its
own. One drug, therefore, counteracted some of the effects
of the other, thereby behaving as an antagonist.
Taken together, these results show that doxo-induced
apoptosis and decrease in cell number depends on the
relocalization of HuR in the cytoplasm and is coupled
with its phosphorylation.
HuR binds to target mRNAs and is loaded on polysomes
following doxorubicin administration
The dependency of apoptosis on HuR could be ascribed
to two previously described mechanisms. One possibility
directly favors the aggregation of the apoptosome com-
plex [21] induced by a truncated form obtained follow-
ing cleavage by caspase 3 and 7. An alternate
mechanism relies on an indirect process through post-
transcriptional stabilization or increases in the transla-
tion of apoptosis related genes [29-32]. We searched for
the presence of the cleaved HuR form after doxo in a
dose dependent experiment. As shown in Figure 4A,
HuR was cleaved minimally and only at 50 μM after
overnight exposure in MCF-7 cells. Conversely, HuR
was exstensively cleaved, although not completely, in
HeLa cells. The presence of both caspases 3 and 7 has
been shown to be necessary to cleave HuR [21]. Despite
a report about the absence of caspase in MCF-7 cells
[33], we and others [34,35] observed the presence of the
activated form of the protein following doxo treatment
(Figure 4B). HuR is known to localize to polysomes and
in stress granules after certain types of stimuli and cell
lesions [36,37]. We observed a massive shifting of the
protein to heavier polysomal fractions following doxo
treatment (Figure 4C), indicating that the protein is
actively participating in the cellular response to the drug
possibly regulating the translation activity of bound
mRNAs.
To explore the HuR response to doxo in terms of HuR
targets, we employed a RIP-chip assay to identify which
mRNAs bind to HuR following doxo treatment. After
immunoprecipitation and hybridization on Agilent
arrays, through a fold enrichment threshold, we filtered
those mRNA species specifically bound to HuR. We
identified mRNAs corresponding to 822 HGNC anno-
tated genes (721 genes with an annotated 3’UTR, Addi-
tional file 2: Table S1) that are bound to HuR and
proportionally enriched in the coimmunoprecipitated
material. To evaluate the reliability of our procedure of
mRNA enrichment, we submitted the 721 HuR-bound
gene list to analysis of functional motifs on the 3’UTR.
Since HuR is known to bind to AREs, we expected to
find a strong overrepresentation of ARE consensus bind-
ing in the 3’UTRs of these genes. The enrichment of the
ARE was high (28% ARE containing genes, p-value 10-11,
Figure 5A) and the significance is maintained even when
removing progressively genes with lower fold enrich-
ment. The first 50 genes are maximally enriched in ARE
(40% of ARE consensus, Table 2). From this list we chose
three genes to confirm the result of the genome wide
analysis by checking the associated amount on the immu-
noprecipitation product via semiquantitative PCR of c-fos
[38], c-myc [39] and SOCS3. As shown in Figure 5B, all
mRNAs confirmed their interaction with HuR after doxo
administration.
These data indicate an involvement of HuR in the
mechanism of apoptosis activation induced by doxo in
our cellular model system that cannot be explained by
the formation of the apoptogenic truncated form of
HuR, and that instead HuR is bound to specific mRNAs
and relocalizes on polysomes after doxo treatment.
Table 1 IC50 Table
MCF-7 MCF-7/DoxoR Loewe interaction index SK-BR-3 SK-BR-3/
NOdoxo
MDA-MB-231 MDA-MB-231/
DoxoR
IC50
(μM)
R
sq
IC50
(μM)
R
sq
MCF_7 MCF-7/
DoxoR
IC50
(μM)
R
sq
IC50
(μM)
R
sq
IC50
(μM)
R
sq
IC50
(μM)
R
sq
Doxorubicin 0,04 0,96 10 0,96 antagonist n.c. 10 0,95 50 0,97 5 0,95 75 0,94
Rottlerin 0,005 0,96 n.c. n.c. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
IC50 Table. IC50s of 24 h drug-treated MCF-7 and MCF-7/DoxoR cells. Data obtained were in luminescence units and analyzed with Graphpad Prism software, n.c.
not convergent, n.d. not done.
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HuR downregulation mediates doxorubicin drug
resistance
Since HuR downregulation promotes a decrease of the
apoptotic response induced by doxo and since rottlerin
antagonizes doxo in inducing loss of viability, we won-
dered if HuR may be implicated in the onset of doxo
resistance. We put MCF-7 cells under doxo selection by
constantly increasing the drug concentration from 0 to
100 nM in a month time scale. We obtained a cell
population, called MCF-7/doxoR, that showed approxi-
mately 250-fold resistance to doxo, compared to the
wild type MCF-7 cells, as observed by the IC50 increase
Figure 3 A. Antagonistic effect of doxorubicin on rottlerin. Sigmoidal inhibition curves for MCF-7 cells treated either with doxo or rottlerin,
or with the two drugs together in a constant ratio of 1:10. The IC50 were calculated by nonlinear regression, using Graphpad Prism software. As
shown by the dashed line, doxo antagonizes the action of rottlerin, producing a shift to the left of its curve. B. Graphic representation of the
combination index calculated following the Loewe model. The combination index of the rottlerin-doxorubicin mixture, never goes below
the additivity reference line of one, indicating that doxorubicin and rottlerin have antagonistic effects. All the experiments were performed in
quadruplicate and repeated at least twice.
Latorre et al. Molecular Cancer 2012, 11:13
http://www.molecular-cancer.com/content/11/1/13
Page 6 of 16
Figure 4 A: HuR apoptotic cleavage is not present in MCF-7 cells. Western blotting analysis on HeLa and MCF-7 whole cell lysate sampled
after an overnight exposure to doxo at different doses 1, 10, 50 μM (+) or not (-). The cleaved form is present in HeLa cells but only in minimal
part in MCF-7 cells. B: Active caspase 3 is present in MCF-7 cells. Western blotting analysis on HeLa and MCF-7 whole cell lysate sampled
after an overnight exposure to doxorubicine 10 μM (+) or not (-). Active caspase 3 is present in MCF-7 cells. C: HuR translocates onto the
translational active polyribosomes. Western blotting analysis on polysomal fractionation samples (1-9). Fractionation was performed on MCF-7
cells grown in standard condition (FCS), starved or treated with doxorubicin 10 μM for 4 h and samples were investigated for the presence of
HuR or PAIP2. In the upper part of the panel is reported a polysomal profile indicating which fractions are enriched in unbound ribosomes
(unb), single ribosomes (mono), low molecular weight polysomes (LMW) or high molecular weight polysomes (HMW). The HMW are the
fractions where the translational active polyribosomes sedimentate and the HuR western bloltting signal after doxorubicin treatment localizes.
PAIP2 is used as control since localization is not affected.
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to approximately 10 μM (Table 1). Further confirmation
of the acquired resistance phenotype came from the
overexpression in MCF-7/doxoR of the ABCG2 trans-
porter, a typical marker and known cause of doxo phar-
macoresistance, while the permissivity to apoptosis was
ascertained by caspase 7 expression (Figure 6A). We
observed a strong downregulation of HuR as the cells
adapted to the presence of doxo. Since we were working
on populations, intrinsically subjected to variability, we
repeated the procedure of doxo selection three times
always obtaining the same clear HuR downregulation.
Moreover, we put under selection other two breast can-
cer cell lines with different charachteristics from MCF-7
cells: MDA-MB-231, triple negative cells, and SK-BR-3,
Her2 positive cells. We obtained a population of MDA-
MB-231 cells resistant to doxo (MDA-MB-231/doxoR)
but not a population of SK-BR-3 (SK-BR/NOdoxoR)
according to the IC50 values measured (Table 1). Inter-
estingly, we observed HuR downregulation in MDA-
MB-231/doxoR but not in SK-BR-3/NOdoxoR (Figure
6B), suggesting that breast cancer cells downregulate
HuR expression only when a deep genetic reprogram-
ming towards pharmacoresistance is taking place and
not as a consequence of the mere presence of doxo.
Therefore, we investigated if HuR downregulation would
have an impact on the levels of bound mRNAs and con-
sequently on their corresponding proteins. We choose
c-Myc and SOCS3, as HuR targets, and observed their
decrease in concomitance to HuR reduction in MCF-7/
doxoR (Figure 6A). Moreover HuR cellular localization
was affected in MCF-7/doxoR since the protein was less
readily distributed in the cytoplasm after doxo adminis-
tration, indicating that alterations of the functionality of
those pathways that trigger HuR translocation occurred
Figure 5 A: Overepresentation analysis of ARE motif in 3’UTR of HuR bound mRNAs. The occurrence of AU rich elements (ARE) was
annotated on the 3’UTR of all human genes using Transterm. Enrichment analysis of ARE motifs was carried out with a modified Fisher test on
the HuR bound genes against the human genome as background. The 721 genes showing significant and specific fold enrichment upon HuR
RIP-Chip were sorted in descending order according to their fold enrichment value. For each n from 1 to 721, the first n genes were considered
in the enrichment analysis and the corresponding enrichment p-value was calculated and shown in the figure, where the x-axis represents the
number of considered genes n, while the y-axis represents the log10 enrichment p-value corresponding to n. The maximum enrichment
significance is reached with n = 683, as marked in the figure by a green vertical line. B: Experimental validation of RIP-Chip. Semiquantitative
RT-PCR on RIP samples immunoprecipitated with anti-HuR antibody (h), whole serum IgG as a negative control (g) and the immunoprecipitation
input (in). RIP analysis was performed on MCF-7 cells grown in standard condition (FCS), starved for 24 h (starved) or treated with doxorubicin
10 μM after starvation. Primers to detect mRNAs that showed an high fold enrichment score (MYC, SOCS3, FOS) during RIP-Chip analysis were
chosen to test the quality of the microarray read out. Primers to detect COX2 and TNFa are literature reported HuR binding mRNAs and the 18S
is a loading and immunoprecipitation control.
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within this cell line during the insurgence of pharma-
coresistance (Figure 6C) while its expression level
remained unchanged (Figure 6E). We also investigated
the expression level of topoisomerase 2A (TOP2A),
since its downregulation is a possible mechanism of
doxo resistance [9] and since it has been very recently
demonstrated that its mRNA is post-transcriptionally
regulated by HuR [40]. Indeed, TOP2A protein levels
were significantly decreased in MCF-7/DoxoR and
MDA-MB-231/DoxoR cells with respect to wild type
populations but not in SK-BR-3/NOdoxoR (Figure 6A).
Although we did not find TOP2A mRNA in our HuR
RIP-chip experiment, TOP2A dowregulation could be a
consequence of HuR dowregulation and explain the loss
of efficacy of doxo.
In order to evaluate if HuR loss caused the acquired
resistance to doxo, we reconstituted HuR expression in
the drug-resistant population. Doxo-induced apoptosis,
measured by the appearance of the caspase 7, was res-
cued after 24 h of HuR transfection and in concomi-
tance with HuR overexpression (Figure 7A, B). Finally,
to demonstrate the importance of HuR in the acquisi-
tion of the resistant phenotype, we measured the toxi-
city effect of doxo in MCF-7/doxoR transfected with
HuR. As can be observed in Figure 7C the dose-
response curve of the transfected cells nearly overlaps
with the curve obtained with the wild type cells, demon-
strating the full reconstitution of the toxic effect of
doxo.
Therefore, downregulation of HuR levels and
decreased activitation of HuR translocation not only is
associated to the acquisition of resistance to doxo but
the maintenance of this phenotype is also dependent on
the presence of the protein.
Discussion
In this study we investigated the role of the protein HuR
during the cellular response to the chemotherapeutic
agent doxo, demonstrating its involvement in doxo-
induced apoptosis and in the onset of in vitro resistance
to this drug in breast cancer cells. We showed that HuR
plays a role in modulating gene expression of MCF-7
cells exposed to doxo in a manner similar to what is
observed after exposure to other DNA damaging agents
[41]. Doxo disrupts the HuR localization equilibrium
and thus increases the cytoplasmic concentration of
HuR (Figure 1). Indeed, we observed an almost two fold
increase in relocalization to the cytoplasm without a
relevant change in the overall total protein amount.
During HuR relocalization, HuR binds to ARE contain-
ing mRNAs (Figure 5B). HuR has been proposed to be
an anti-apoptotic protein due to its ability to bind and
prolong the stability of anti-apototic genes such as BCL-
2 and MCL-1 [32]. On the other side, a direct role for
Table 2 List of mRNAs bound to HuR
Gene
symbol
HuR fold
enrichment
AU-rich stability element
(ARE)
ZNF184 39.636307 0
C7orf38 36.77381 0
ZNF14 36.34539 0
MYC 33.380974 0
KLF10 31.022799 0
ZNF624 30.735386 0
KIAA1383 27.78753 0
WDR5B 24.241896 0
ZNF443 24.03738 0
ZNF606 23.884226 0
EGR3 22.023645 0
ZNF750 21.599466 0
ZBTB6 21.308832 1
ZNF367 20.524889 2
ZNF44 18.437605 0
ZNF658 18.434893 0
NFKBIA 17.987656 1
FEM1C 17.382252 0
FAM5B 17.253944 1
TRAF6 17.018587 0
ZNF319 16.993372 0
NUAK2 16.958181 4
ZNF564 16.866674 0
EXOC8 16.58628 3
HIST1H4B 16.585716 0
ZNF217 16.54123 1
ZBED5 16.376629 0
PNRC1 16.23357 0
THAP6 16.157799 1
PTGER4 16.002222 0
ZIC5 15.810935 1
TRIB1 15.656507 0
KIAA1586 15.557861 0
PLEKHF2 14.738077 0
ZNF643 14.671463 0
ZNF267 14.121434 1
EGR1 13.995536 0
ZNF709 13.961123 1
SOCS3 13.905058 2
TIPARP 13.888878 4
CDCA4 13.859092 1
FOS 13.489109 2
ZNF764 13.478119 4
PLK2 13.028596 2
DLC1 12.873251 0
ELF2 12.868533 0
ZNF773 12.810777 0
PPP1R3B 12.796747 0
SOCS6 12.379617 1
NRIP1 12.327525 0
List of mRNAs bound to HuR: first 50 genes, ordered by fold enrichment,
identified by RIP-Chip of HuR in the presence of doxorubicin.
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HuR in the molecular processes of apoptosis was first
demonstrated by Gallouzi et al. [21] where they showed
that, in HeLa cells exposed to staurosporine, the down-
regulation of HuR delays apoptosis. In this case, HuR
plays an active role in the process, mediated by caspase
3 and 7 cleaving of cytosolic HuR that, after being trun-
cated, helps to promote cell death by binding to pp32.
Therefore, HuR probably plays a double role in apopto-
sis, including an indirect role by positively controlling
gene expression of apoptotic genes and a direct role by
helping, at the molecular level, the apoptotic machinery
to proceed. In our study we demonstrated that in MCF-
7 cells HuR is necessary to allow the apoptotic response
induced by doxo. When we silenced this gene the
response decreased (Figure 2A), but the truncated form
of HuR did not appear to be involved in this mechanism
since we observed only very low levels of the truncated
form after doxo administration (Figure 4A). Therefore,
in order to elucidate the role of HuR in regulating apop-
tosis or pro-survival we used a drug, rottlerin, known to
block HuR phosphorylation. This drug was originally
identified as a PKCδ inhibitor [42] but, later on, its
mechanism of action was correlated to its mitochondrial
uncoupler activity [43]. Recently, it has been observed to
impair the ability of PKCδ to phosphorylate the Ser318
residue of HuR in colon cancer cells [44]. We observed
Figure 6 A. Characterization of MCF-7/DoxoR cells. Western blotting on whole cell lysates from parental (MCF-7) and doxorubicin resistant
(MCF-7/DoxoR) MCF-7 cells. HuR, c-Myc, Socs3 and TOP2A are down regulated in the MCF-7/DoxoR cells in comparison with the parental,
ABCG2 is up regulated. Caspase 7 expression level is not affected. Beta tubulin is the loading control. B. Characterization of MDA-MB-231/
DoxoR and SK/NOdoxoR cells. Western blotting on whole cell lysates from parental (MDA-MB-231, SK) and doxo resistant (MDA/DoxoR) and
doxo exposed (SK/NOdoxoR) cells. HuR and TOP2A are down regulated in the MDA-MB-231/DoxoR cells. Beta tubulin is the loading control.
Protein quantification measured by densitometric analyses on three independent western blots. * p-value < 0.05 with respect to starved
conditions. C. HuR does not translocate from the nucleus to the cytosol after doxorubicin treatment in MCF-7/DoxoR cells.
Immunofluorescence (HuR in green, counterstaining DAPI in blue) on MCF-7 cells starved for 24 h and treated at increasing doxo concentration
(from 1 to 50 μM) for 4 h. Quantification of HuR cytoplasmic translocation measured on immunofluorescence images by calculating the ratio of
intensity signal in the nucleus and in the cytoplasm. D. An average of 300 cells for each experimental conditions were used. Z-score below zero
indicates nuclear localization, above zero cytoplasmic localization. Quantification of HuR protein translocation after 10 μM doxo for 4 h measured
by densitometric analyses on three independent western blots. E. Quantification of total HuR protein measured by densitometric analyses on
three independent western blots. No change was observed neither in protein amount nor in protein translocation during doxo treatment.
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that rottlerin was able to inhibit also HuR translocation
after doxo treatment (Figure 4B). Rottlerin elicited a
strong toxic effect on MCF-7 cells without inducing
apoptosis. The HuR protein has been described as
involved in tumor aggressiveness [45], cancer ethiology
[19] and proposed as a potential drug target [46,47] in
cancer but, when we coadministered rottlerin and doxo,
we observed an antagonistic effect of the two drugs on
cell viability. This observation reveals that the two drugs
have opposite effects at the molecular level on cellular
pathways and is consistent with the opposite effects that
the two drugs exert on HuR. Doxorubicin induces apop-
tosis according to the presence of HuR and accumulated
HuR in the cytoplasm, while rottlerin maintained HuR
in the nucleus and had a low impact in inducing apop-
tosis. The observation that HuR is downregulated at the
protein level in resistant populations as MCF-7/doxoR
and MDA-MB-231/DoxoR but not in cells that did not
acquire pharmacoresistance, although exposed to same
doses of doxo, as (SK-BR-3/NOdoxoR) cells is in line
with its key activity in doxo-induced cytotoxicity. Cells
resistant to doxo-induced apoptosis activate the expres-
sion of drug extrusion channels, of which we verified
ABCG2 as being the major mechanism of drug resistance
mediated by the overexpression of detoxifying channels as
ABCG2 or ABCB1 [5,6] while the involvement in the pro-
cess of post-transcriptional regulators, such as HuR, is not
widely explored. The activity of HuR has been correlated
as a proactive factor in the onset of drug resistance in
glioma [48] and against UVR [49]. Moreover in MCF-7
cells cytoplasmic HuR was proposed as a key mediator of
tamoxifen resistance, due to its ability to stabilize mRNAs
that encode proteins responsible for the activation of the
MAPK pathway [50]. Conversely, pancreatic cancer cells
overexpressing HuR are more sensitive to gemcitabine
compared to control cells [51] due to a stabilization of
Figure 7 A: Transfection with HuR overexpressing plasmid. Western blotting on whole cell lysates from parental (MCF-7) and doxorubicin
resistant MCF-7 (MCF-7/DoxorR) cells, mock transfected, to detect the HuR expression level also in the presence (+) of HuR overexpressing
plasmid. Beta tubulin was used as loading control. B. Caspase 7 activation in MCF-7/DoxoR. Western blotting on whole cell lysates from
parental (MCF-7) and doxorubicin resistant MCF-7 (MCF-7/DoxorR), mock transfected, to detect caspase 7 activation in the presence of doxo C.
HuR revert MCF-7 doxorubicin resistance. Sigmoidal inhibition curves of MCF-7 wild type (WT), doxorubicin-resistant (MCF-7/DoxoR), and
MCF-7/DoxoR trasfected with a plasmid containing the coding sequence of HuR (MCF-7/DoxoR + HuR). Cells were exposed to different
concentration of doxorubicin for 24 h before being assayed. As demonstrated by the dashed line, the doxo toxic effect on HuR transiently
transfected-DoxoRes cells was similar to the one exerted on MCF-7.
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the deoxycytidine kinase (dCK) mRNA, encoding the
enzyme that metabolizes and thereby activates gemcita-
bine. Very recently Srikantan et al. [40] demonstrated that
HuR stabilizes TOP2A mRNA and competes with the
microRNA miR-548c-3p, being their combined action a
way of controlling TOP2A expression levels and determin-
ing the effectiveness of doxo. In our case, we have clear
indications that, in the absence of HuR, doxo cannot elicit
apoptosis both in MCF-7 wild type cells and in the corre-
sponding doxo-resistant cells. In our MCF-7 and MDA-
MB-231 doxo-resistant cells the resistance mechanism
could lay on the post-transcriptional regulation of TOP2A,
although we did not find TOP2A messenger bound to
HuR or downregulated, in the microarray experiment, at
the cytoplasmic level. As support to this hypothesis we
also found a slower HuR cytoplasmic translocation after
doxo administration in MCF-7/DoxoR cells, suggesting
that, not only HuR expression level but also the mechan-
isms activating HuR translocation are altered in resistant
cells. The perfect reversion of doxo resistance by HuR
re-expression in the experiment of genetic rescue, not-
withstanding the permanence of ABCG2 transporter upre-
gulation, further demonstrates the key role exerted by this
protein to mediate efficacy of doxorubicin.
Conclusions
HuR has been correlated in many studies with increased
malignancy of tumors, but in this case its expression is a
clear indication of the efficacy of doxo treatment. In line
with this observation, its downregulation in resistant cells
is a determinant of this resistance and therefore its down-
regulation in cancers treated with doxo could be a marker
of pharmacoresistance. In conclusion, although our study
was conducted in vitro and its generality in vivo must be
demonstrated, we can suggest taking particular care in the
interpretation of HuR expression levels and cell localization
in cancer, since its downregulation could be expected to be
an indicator of bad prognosis in tumors treated with doxo.
Methods
Cell lines
MCF-7, MDA-MB-231, SK-BR-3 breast cancer cell lines
where were cultured in complete DMEM (Lonza) sup-
plemented with 10% fetal calf serum (FCS- Lonza),
2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin (Lonza), or OptiMem (Lonza). Doxorubi-
cin resistant cells were derived from the parental cell
line by continuously exposing cells to increasing doxor-
ubicin concentration. Doxorubicin was removed from
medium 3 days before any experiments were run.
Chemicals and antibodies
Doxorubicin hydrochloride D1515 Sigma, Anti-HuR sc-
71290 santa cruz, Anti-myc 06-340, Millipore normal
mouse total serum IgG sc-2025 santa cruz, Anti-c-myc
sc 40 santa cruz, anti-SOCS3 sc7009 santa cruz, anti-
Caspase 7 sc 56067 santa cruz, anti-beta-tubulin sc
55529 santa cruz, anti-ABCG2 MAB995 R&D, anti-LDH
L7016 Sigma, Caspase Glo 3/7 codice prodotto: G8091
Promega, anti-H3 ab1791 Abcam, TransIT-LT1 Trans-
fection Reagent MIR2300 Mirus, HuR siRNA HuR
siRNA (h): sc-35619 santa cruz, c-Myc siRNA c-Myc
siRNA (h): sc-29226 santa cruz, scrambled control Con-
trol siRNA-A sc-37007 santa cruz, anti-active caspase 3
ab13847 Abcam
Apoptosis assays
MCF-7 or MCF-7/DoxoR cells were seeded in 96-well
plates (Corning, Lowell, MA) at a density of 10000 cells/
well. The following day, the test drug was added and the
cells were exposed to it for 4 h before being assayed
using a luminescence-based apoptosis kit (Caspase-Glo®
3/7 Assay, Promega, Madison, WI). Statistical analysis
was performed using T-test algorithm in Xcel (Micro-
soft) software.
Plasmid preparation
HuR CDS was PCR amplified from cDNA and blunt
inserted in pENTR vector (Gateway system, Invitrogen)
using pENTR/SD/D-TOPO cloning system. HuR CDS
was then recombined into pT-Rex-DEST30 destination
vector for expression in mammalian cells. The cloning
procedure was made according to manufacturer instruc-
tions. Oligos used for PCR amplification were: Hur-
entr-FOR CACC ATGTCTAATGGTTATG AAG ACC
AC, Hur-entr-REV TCA TTA TTT GTG GGA CTT
GTT GGT TTT G. CDS sequence and orientation into
plasmids were verified by sequencing.
Toxicity assays
MCF-7 or MCF-7/DoxoR cells were seeded in 96-well
plates (Corning, Lowell, MA) at a density of 10000 cells/
well. The following day, the test drug was added and the
cells were exposed to it for 24 h before being assayed
using a luminescence-based viability kit (CellTiter-Glo®,
Promega, Madison, WI). The data were analyzed with
GraphPad Prism 5.0 (GraphPad, San Diego, CA) soft-
ware. The IC50 was determined by fitting the data point
with the sigmoidal curve and calculating the dose neces-
sary to achieve half of the maximum effect. The combi-
nation index was measured using Mixlow software
(version 1.0.0) using dose response curves obtained by
mixing Rottlerin and doxo at a fixed ratio of 10:1.
Immunofluorescence
Cells were plated on acid-washed glass coverslips on
plates and maintained in the appropriate culture med-
ium and experimental conditions. In brief, cells were
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fixed in PHEM buffer (36.8 g/l PIPES, 13 g/l HEPES, 7.6
g/l EGTA, 1.99 g/l MgSO4, titrated to pH 7.0 with
KOH) plus 3.7%paraformaldehyde (PFA) for 15 min at
room temperature. Cells were then treated for 5 min
with HEPES-based permeabilization buffer (300 mM
sucrose, 0.2% Triton X-100) and then for 15 min with
blocking buffer (3% Bovine Serum Albumin in PBS). Pri-
mary antibodies and secondary fluorophore conjugated
(Alexa 488) antibodies were diluted in PBS + BSA 0.2%.
DAPI (1.5 μg/ml) in PBS + BSA 0.2% was used as coun-
terstaining. Nikon A1R Confocal Laser Microscope, exi-
tation:488 nm and 405 nm 60× APO Oil objective was
used for imaging. Cells for fluorescence quantification of
the nucleus-cytosol translocation were imaged using an
Zeiss 40× LD Plan-Neofluar 40x/0.60 on a Zeiss Axio
observer Z1, excitation 360/40 or 490/20. Images were
processed by Columbus Software (Perkin Elmer) and
nucleus-cytosol translocation was expressed in z-score
(z = x-μ/δwere μ and δ are respectively the mean and
the standard deviation of the whole population of sig-
nals and x is the mean the single experimental point) of
the ratio: nucleus florescence/cytosol fluorescence, ana-
lyzing 300 cells for each experimental point.
2D gel electrophoresis
About 250-400 μg of protein from total extracts were
added to 180 μl rehydration buffer (8 M urea, 2%
CHAPS, 20 mM dithioerythritol, 0.8% IPG buffer, carrier
ampholytes pH 6-11 Linear). Samples were applied onto
ceramic strip holders (GE) connecting two electrodes, in
contact with polyacrylamide gel strips (immobiline dry
strips GE ph 6-11 7 cm 17-6001-94). Isoelectrofocusing
(IEF) was performed on IPGphor (GE) with 2 different
protocols according to the manufacturer recommenda-
tions. Second dimension electrophoresis was performed
using a Protean II apparatus (Bio-Rad). Strips were
soaked first in Equilibration buffer (EB: 6 M urea, 3%
SDS, 375 mM Tris pH 8.6, 30% glycerol, 2% DTE), then
in EB containing 3% iodoacetamide (IAA) and traces of
bromophenol blue (BBP). Subsequently, strips were
applied onto 10%-12% PA gels and western blotted.
RNA immuneprecipitation (RIP)
12 × 106 MCF-7 cells cultured in the different experi-
mental conditions were syringed by an U-100 insulin
needle in 500 ul lyses NT2 buffer (50 mM tirs-HCl
pH7.7, 150 mM NaCl, 1 mM MgCl2; 0.05%NP40, 1 U/
ul RNase IN, 20 mM DTT, 1% BSA, Protease inhibitor
cocktail manufacturer’s recommended) chilled at 4°C.
Lysate was centrifuged at 10000 g for 10 min then the
supernatant was pre-cleared by interaction with protein-
A-coated agarose beads (equilibrated in NT2 buffer) for
an overnight at 4°C in constant shaking (100 ul slurry
beads/500 ul lysate). 150 ul of the pre-cleared lysate
were put to interact with protein A coated agarose
beads anti-HuR antibody (or control IgG) conjugated
for 6 h at 4°C then washed twice in NT2 buffer. 20 ul
Protein-A-coated slurry agarose beads were conjugated
with 4 ug antibody at room temperature for 2 h, washed
and equilibrated in NT2 lysis buffer before use. RNA
was isolated from the different samples (immunoprecipi-
tated anti-HuR, IgG and precleared input) by TriZol as
manufacturer’s recommended, retrotranscribed into
cDNA by MBI-Fermentas kit and used as template for
PCR analysis. Primers used are FOS F:ATGAGCCTT
CCTCTGACTCG, R:ACGCACAGATAAGGTCCTCC.
MYC F:GCCACGTCTCCACACATCAG, R:TGGTGC
ATTTTCGGTTGTTG. SOCS3 F:TATTAGGAGATGC
TTGAAGAA, R:ATAGTGCTCTTTATTATAAAT.18S,
F:TACCTGGTTGATCCTGCCAGTAGCATA, R:AGG
AACCATAACTGATTTAATGAGCCAT, TNF:F, AAG-
CATGATCCGGGACGTGGAGCTGGCCGA, R:TCT
GGGGGCCGATCACTCCAAAGTGCAGCA, COX2F:
GTGCGCGGTCCTGGCGCTCAGCCATACAGC, R:
AAGGCTTCCCAGCTTTTGTAGCCATAGTCA
Microarray data analysis
RIP samples and cytosolic RNA samples were labeled
using a Quick Amp dual Colour 5190-0444 and hybri-
dized on a Gene expression All Human Genome (4 × 44
K) oligo microarray kit Aglient Thecnology G4112F.
Hybridized microarray slides were scanned with an Agi-
lent DNA Microarray Scanner (G2505C, Agilent Tech-
nologies, Santa Clara, CA) at 5 micron resolution with
the manufacturer’s software (Agilent ScanControl 8.1.3).
The scanned TIFF images were analyzed numerically
using the Agilent Feature Extraction Software version
10.7.7.1 according to the Agilent standard protocol
GE1_107_Sep09. Following analyses were carried with
GeneSpring GX 9 software. All microarray data are avail-
able through the Gene Expression Omnibus database
http://www.ncbi.nlm.nih.gov/geo/ using the accession
number GSE33055.
Comparison between cytoplasmic RNA samples of control
MCF7 cells with doxorubicin treated cells
Experiments were conducted in biological quadruplicate.
Microarray signals were log2 transformed, normalized
using 75th percentile-shift and baseline transformed to
the median of all samples. Probes flagged as absent in
all samples were removed. Probes with high coefficient
of variation (> 50%) between replicas of the same condi-
tion were removed. Differentially expressed genes were
detected applying a significance threshold on t-test
unequal variance (Benjamini-Hochberg corrected
p-value < 0.05) and a fold change threshold (absolute
fold change > 2).
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Comparison between HuR RIP samples and IgG RIP samples
of doxorubicin treated cells
Experiments were conducted in biological quadruplicate.
Microarray signals were log2 transformed. Normalization
and baseline transformation were not applied. Probes
flagged as absent in all samples were removed. Probes
with high coefficient of variation (> 50%) between replicas
of the same condition were removed. Differentially
expressed genes (specifically bound by HuR) were detected
applying a significance threshold on t-test unequal var-
iance (Benjamini-Hochberg corrected p-value < 0.05) and
a fold change threshold (positive fold change > 2).
Comparison between HuR RIP samples and cytoplasmic
RNA samples of doxorubicin treated MCF7 cells
Experiments were conducted in biological triplicate.
Microarray signals were log2 transformed, normalized
using 75th percentile-shift and baseline transformed to the
median of all samples. Probes flagged as absent in all sam-
ples were removed. Probes with high coefficient of varia-
tion (> 50%) between replicas of the same condition were
removed. Differentially expressed genes were detected
applying a significance threshold on t-test unequal var-
iance (Benjamini-Hochberg corrected p-value < 0.05) and
a fold enrichment threshold (absolute fold change > 2).
Ontological enrichment analysis
The DAVID [52] resource was used for gene-annotation
enrichment analysis of DEG lists with categories from the
following resources: PIR http://pir.georgetown.edu/, Gene
Ontology http://www.geneontology.org, KEGG http://
www.genome.jp/kegg/ and Biocarta http://www.biocarta.
com/default.aspx pathway databases, PFAM http://pfam.
sanger.ac.uk/ and COG http://www.ncbi.nlm.nih.gov/
COG/ databases. The significance of overrepresentation
was determined at a false discovery rate of 5% with Benja-
mini multiple testing correction.
Analysis of 3’ UTRs
Human 3’ UTR sequences of human genes represented
on the Agilent array were downloaded from the UCSC
genome browser http://genome.ucsc.edu/, assembly
GRC37/hg19. For each HGNC gene a single 3’ UTR
sequence was determined as the longest among all the
gene transcript variants. AU rich elements were mapped
to 3’UTR sequences using the Transterm ARE pattern
“UAUUUAUWW” [53]http://uther.otago.ac.nz/. Motif
enrichment analyses were implemented in R: motif
enrichment was assessed calculating the EASE Score
[54], a modified Fisher Exact P-Value introduced by
DAVID developers http://david.abcc.ncifcrf.gov/home.
jsp. In all enrichment analyses, the 14678 human genes
with 3’ UTR longer than 9 nucleotides were used as
background set.
No ethics committee approval has been requested as
the research has been entirely performed with commer-
cial cell lines.
Additional material
Additional file 1: Figure S1. Doxorubicin induced apoptosis. Annexin-V
FACS assay on MCF-7 cells treated with different doxorubicin (doxo)
concentration for 18 h or not (untreated). The upper left dot plot
indicates which area is occupied by necrotic, apoptotic or living cells
respectively. Freeze and tow (F&T) sample was used as necrosis positive
control and cycloexamide 10 μM (CXM) was used as apoptosis positive
control.
Additional file 2: Table S1. List of mRNAs bound to HuR in the
presence of doxorubicin. The complete list of mRNAs precipitated with
HuR during RIP-Chip. Probe indicates the Agilent reference number, gene
symbol is the HGNC symbol, HuR fold enrichment is the fold enrichment
of mRNA bound to HuR in comparison to cytoplasmic amount, AU-rich
stability element is how many AREs are present in the 3’UTR of the
mRNA according to TRANSTERM, description is gene annotation.
Abbreviations
3’UTR: 3’ UnTraslated region; ARE: AU rich element; BP: Biological process;
DEGs: Differentially expressed genes; Doxorubicin: Doxo; HCS: High content
screening; IgG: Immunoglobulin type G; GO: Gene ontology; KI: Kinase
inhibitor; MDR: MultiDrug resistance; PCR: Polymerase chain reaction; RBP:
RNA binding protein; RIP: RibonucleoProtein immunoprecipitation; UVR:
Ultraviolet radiation.
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